Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

Podobne knjige/članki

• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  od: Janjigian, Yelena Y., et al.
  Izdano: (2011)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  od: Oxnard, Geoffrey R., et al.
  Izdano: (2011)
• Core Needle Lung Biopsy Specimens: Adequacy for EGFR and KRAS Mutational Analysis
  od: Solomon, Stephen B., et al.
  Izdano: (2010)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  od: Zakowski, Maureen F., et al.
  Izdano: (2009)
• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
  od: Price, Katharine A., et al.
  Izdano: (2010)